KRAS and neoplasm: For example, recent work by Downward and colleagues showed that KRASG12C inhibition in a KRAS-mutant mouse model of NSCLC suppresses the downstream function of MYC, resulting in up-regulated interferon signalling, leading to reduced tumour immunosuppressive cytokine production, enhanced infiltration and activation of CD8 + T cells, and increased neoantigen presentation by MHCs (Fig. 1, Fig. 2) [7].